Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2015-06-05 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2015年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, voting procedures, and results of a specific shareholders' meeting (the 2015 second extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting and resolutions passed. It is not a report of financial results, audit, or management discussion, nor is it a notice or announcement of voting results. Instead, it is a legal opinion related to a shareholders' meeting. This type of document does not fit into categories like Annual Report, Earnings Release, or Proxy Solicitation. It is best classified under Regulatory Filings (RNS) as a legal compliance document related to corporate governance and shareholder meetings that does not fit other specific categories.
2015-06-05 Chinese
北京德恒（昆明）律师事务所关于股份有限公司2014年授予股权激励所涉限制性股票解锁事宜的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the unlocking of restricted stock related to a 2014 equity incentive plan of a company. It references compliance with laws and regulations, company internal approvals, and conditions for unlocking restricted stock. The document is a standalone legal opinion and does not contain financial statements, audit results, or financial performance data. It is not an annual report, audit report, or earnings release. It is also not a regulatory filing or announcement of a report publication. The document is best classified as a Legal Proceedings Report (LTR) because it deals with legal compliance and conditions related to stock incentive unlocking, which is a legal matter rather than a financial report or announcement.
2015-06-05 Chinese
独立董事关于公司2014年授予股权激励所涉限制性股票解锁条件成就的独立意见
Governance Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the fulfillment of conditions for unlocking restricted stock under a 2014 equity incentive plan. It references regulatory compliance and company internal rules related to stock incentives. The document is short (1022 characters) and focuses on a specific governance and compliance matter related to stock incentives, not a full financial report or earnings release. It is not an announcement of a report but an independent opinion on a governance issue related to equity incentives. This fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices, including stock incentive plans and related approvals.
2015-06-05 Chinese
北京德恒（昆明）律师事务所关于股份有限公司2014年授予股权激励所涉限制性股票解锁事宜的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the unlocking of restricted stock related to a 2014 equity incentive plan of a company. It references compliance with company law, securities law, and regulatory requirements from the China Securities Regulatory Commission. The document details the conditions for unlocking restricted stock, the procedures followed, and the legal opinion on the legitimacy of the unlocking. It is not a financial report, audit report, earnings release, or any form of shareholder meeting material. It is a legal proceeding related document providing a formal legal opinion on a corporate action (stock unlocking under an equity incentive plan). Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 2453 characters, which is relatively short but contains substantive legal content rather than just an announcement or certification, so it is not RNS or RPA.
2015-06-05 Chinese
2015年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2015 second extraordinary shareholders' meeting of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, location, attendance, voting results, and legal witness statements. The content focuses on the announcement of the shareholders' meeting resolutions and voting outcomes rather than the full meeting materials or presentations. The document length is short (1788 characters), and it is an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2015-06-05 Chinese
监事会关于公司2014年授予股权激励所涉限制性股票解锁条件成就的审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's audit opinion regarding the achievement of unlocking conditions for restricted stock granted under the company's 2014 equity incentive plan. It references specific regulatory frameworks and company internal rules related to stock incentives and compliance. The content is focused on the review and approval of stock incentive unlocking conditions rather than a full financial report or announcement. It is not an annual report, earnings release, or management report. It is also not a regulatory filing or announcement of a report publication. The document is a formal audit opinion related to internal compliance and stock incentive conditions, fitting the category of Audit Report / Information (AR). The document length is short and specific, but it contains substantive audit opinion content rather than just an announcement or certification letter, so it is not RNS or RPA. FY 2014
2015-06-05 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.